Literature DB >> 8099841

Gain of function mutations in p53.

D Dittmer1, S Pati, G Zambetti, S Chu, A K Teresky, M Moore, C Finlay, A J Levine.   

Abstract

We report that the expression of murine or human mutant p53 proteins in cells with no endogenous p53 proteins confers new or additional phenotypes upon these cells. Mutant p53 proteins expressed in cell lines lacking p53 resulted in either enhanced tumorigenic potential in nude mice ((10)3 cells) or enhanced plating efficiency in agar cell culture (human SAOS-2 cells). Also, mutant human p53 alleles, unlike the wild-type p53 protein, could also enhance the expression of a test gene regulated by the multi-drug resistance enhancer-promoter element. These data demonstrate a gain of function associated with p53 mutations in addition to the loss of function shown previously to be associated with mutations in this tumour suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099841     DOI: 10.1038/ng0593-42

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  257 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

5.  Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.

Authors:  Sergio Acin; Zhongyou Li; Olga Mejia; Dennis R Roop; Adel K El-Naggar; Carlos Caulin
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

6.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

7.  Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.

Authors:  S K Thukral; G C Blain; K K Chang; S Fields
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

8.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

9.  An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele.

Authors:  T Nakamura; J G Pichel; L Williams-Simons; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.